Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.

International journal of cancer - 15 Nov 2011

Bachmann Hagen S, Heukamp Lukas C, Schmitz Klaus J, Hilburn Caroline F, Kahl Philip, Buettner Reinhard, Nückel Holger, Eisenhardt Andreas, Rübben Herbert, Schmid Kurt Werner, Siffert Winfried, Eggert Angelika, Schramm Alexander, Schulte Johannes H

Abstract excerpt

Molecular markers predictive of prostate cancer prognosis are urgently needed. Overexpression of the antiapoptotic protein, Bcl-2, has repeatedly been shown to be associated with adverse outcome in this malignancy. We hypothesized that a regulatory BCL2 -938C>A promoter polymorphism, which significantly affects promoter activity and Bcl-2 expression in different malignancies, may influence survival. Reporter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Polymorphism, Single Nucleotide

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Prostatic Neoplasms

Share to Proto-Oncogene Proteins c-bcl-2

Source

Identifiers

PMID: 21207420
DOI: 10.1002/ijc.25904

Genes

BCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma.PMID 21207420Read ↗

BCL2 genotypes and prostate cancer survival.Semantic proximity Read ↗

The AA genotype of the regulatory BCL2 promoter polymorphism ( 938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients.Semantic proximity Read ↗

The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.Semantic proximity Read ↗

Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia.Semantic proximity Read ↗

Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer.Semantic proximity Read ↗

Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.Semantic proximity Read ↗

Polymorphic variants of the CASP3, CASP9, BCL-2 and NKX3-1 genes as candidate markers for prostate cancer susceptibility and poor prognosis.Semantic proximity Read ↗

Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme.Semantic proximity Read ↗

The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.Semantic proximity Read ↗

Relationship of Common Variants in PRL-3 Gene With Susceptibility and Prognosis of Prostate CancerSemantic proximity Read ↗

Role of Bcl-2 -938 C>A polymorphism in susceptibility and prognosis of cancer: a meta-analysis.Semantic proximity Read ↗

BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.